Strategic partnerships Cerba Research is expanding through partnerships (example: Ozette Technologies) to enhance high-dimensional cytometry, AI-driven single-cell analytics, and spectral flow capabilities, presenting a cross-sell opportunity for integrated translational research services and advanced data analytics collaborations.

Global network With a worldwide network of 1000 labs and data from over 85 million patients, Cerba offers scalable, end-to-end clinical testing coverage across multiple therapeutic areas, creating upsell opportunities for multinational trials and harmonized testing across regions.

Vaccine and infectious disease focus Cerba’s history of enabling vaccine development and infectious disease R&D, including COVID-19 tools, points to continued demand for innovative bioanalytical testing, immunology assays, and translational infrastructure for upcoming vaccines and outbreak-responsive programs.

High-growth capabilities Ability to sequence 1000-plus whole human genomes per week and advanced omics testing (spatial omics, IHC, flow cytometry) positions Cerba to capture share in precision medicine programs, gene and cell therapies, and biomarker-driven trials.

Digital and data readiness Cerba leverages cloud and HIPAA-compliant data management, along with a modern tech stack, enabling secure data integration and analytics for complex trials; this opens cross-sell prospects for data management, bioinformatics services, and digital trial enablement platforms.